Table 1.
Efficiency of EGFP mRNA lipofection and electroporation in dendritic cells: comparison of different studies
| Lipofection | Electroporation | ||||
|---|---|---|---|---|---|
| Study | DC type | A | B | A | B |
| Strobel et al. [19] | iMo-DC | 16%n.s. | 7·6%n.s. | ||
| Van Tendeloo et al. [20] | iMo-DC | 7·5% | 9% | 63% | 78% |
| mMo-DC | 4% | 5% | 33% | 41% | |
| 34-LC | 0% | 0% | 50% | 62% | |
| 34-DC | 0% | 0% | 73% | 85% | |
| Saebφe-Larssen et al. [22] | iMo-DC | – | n.d. | 95% | |
| Kalady et al. [23] | iMo-DC | n.d. | 12% | n.d. | 50% |
| Lundqvist et al. [24] | iMo-DC | 4%n.s. | 60%n.s. | ||
| 34-DC | – | 40%n.s. | |||
| Ponsaerts et al. [21] | iMo-DC | – | 73% | 85% | |
| Van Tendeloo et al. [25] | BM-DC | – | 70%n.s. | ||
Efficiencies are given as the number of EGFP-positive cells measured by flow cytometry. DC type: iMo-DC, human immature monocytes-derived dendritic cells; mMo-DC, human mature monocytes-derived dendritic cells; 34-DC, human CD34 progenitor-derived Langerhans cells; 34-DC, human CD34 progenitor-derived dendritic cells; BM-DC, murine bone-marrow derived dendritic cells. A: Transfection efficiency on total DC population (including dead cells). B: Transfection efficiency on viable DC population. n.d.: no data. n.s.: not specified A or B.